Fig. 1From: Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trialIncremental net benefit estimate for all patients (upper graph, dashed line), KRAS-WT (middle graph, solid line), and KRAS-MUT (lower graph, hashed line) and 95% confidence intervals (dashed lines)Back to article page